Resolute Capital Asset Partners’s Verona Pharma VRNA Stock Holding History

Resolute Capital Asset Partners’s Portfolio VRNA Stock Details VRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-30,000	Closed	-$1.39M	–	55
2024 Q4	$1.39M	Sell	30,000 -80,000	-73%	-$3M	0.75%	28
2024 Q3	$3.17M	Buy	110,000 +60,000	+120%	+$1.48M	1.65%	23
2024 Q2	$723K	Buy	+50,000	New	+$730K	0.42%	39
2023 Q2	–	Sell	-115,000	Closed	-$2.31M	–	53
2023 Q1	$2.31M	Sell	115,000 -70,992	-38%	-$1.53M	1.69%	27
2022 Q4	$4.86M	Buy	+185,992	New	+$2.48M	4.34%	6

Other funds holding VRNA

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

SPPAM

Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Resolute Capital Asset Partners's VRNA Position: Q1 2025 in Review

Resolute Capital Asset Partners sold out of Verona Pharma (VRNA) in Q1 2025, closing a stake of 30,000 shares — an estimated $1.39M sold.

Resolute Capital Asset Partners first reported a position in VRNA in Q4 2022 and held it in 5 quarters. The position peaked at $4.86M in Q4 2022. 258 funds tracked by Wall St. Rank hold VRNA as of Q1 2025.

Resolute Capital Asset Partners reported no remaining Verona Pharma position as of Q1 2025 after selling out during the quarter.
Resolute Capital Asset Partners sold 30,000 Verona Pharma shares in Q1 2025, an estimated $1.39M.
Resolute Capital Asset Partners first reported a position in Verona Pharma in Q4 2022 and held it in 5 quarters.
Resolute Capital Asset Partners's Verona Pharma position peaked at $4.86M in Q4 2022.
258 funds tracked by Wall St. Rank held Verona Pharma as of Q1 2025.

Based on Resolute Capital Asset Partners's 13F filing for Q1 2025, filed 14 May 2025.